Providing confidential valuation of BiomX, a clinical stage microbiome therapeutics company.
Tel Aviv, Israel / Branford, CT, US — 27 January 2021
Flow Partners acted as a financial advisor to a leading Israeli early-stage venture capital investor Elevator Fund on a portfolio valuation and strategic review of BiomX, a biotech microbiome company focused on developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as bacteria that affect the appearance of the skin.
Providing confidential valuation of BiomX, a clinical stage microbiome therapeutics company.
Tel Aviv, Israel / Branford, CT, US — 27 January 2021
Flow Partners acted as a financial advisor to a leading Israeli early-stage venture capital investor Elevator Fund on a portfolio valuation and strategic review of BiomX, a biotech microbiome company focused on developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as bacteria that affect the appearance of the skin.
Overview
Elevator Fund required an actionable valuation advice for BiomX in order to accurately balance and keep pulse on their venture portfolio.
We have provided an independent valuation opinion that included development pipeline analysis, risk-adjusted NPV (rNPV), comparable environment analysis, portfolio impact, operational benchmarking, green/red flag analysis and more.
This transaction highlights our strong track record in digital health and biotech space, having also advised and valued companies like AVE & YOU (personalized skincare) or Code Pharma (pharmaceuticals).
About BiomX
BiomX (NYSE and TASE: PHGE) is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
About Elevator Fund
Elevator Fund invests in exceptional early-stage startups globally. Elevator leads and syndicates seed rounds, investing between $250K-$1M in innovative companies located in Israel, Europe and the US. Elevator invests in areas of fintech, new media, digital health and other emerging fields.
About Flow Partners
Flow Partners is a modern advisory firm providing independent corporate finance advice to companies and investors that shape the global digital ecosystem. Flow was founded in 2020 and operates globally with presence in London, Berlin, Warsaw and Miami.
For more information, please visit www.flowpartners.io
Enquiries
For all enquiries please contact the team at [email protected]